View source for Diagnostic Kits/Diagnosis or drug- Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine

'''Kling. Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine?''' EMBO reports (2007) vol. 8 (10) pp. 903-6. Accessed December 14, 2009 at http://www.nature.com/embor/journal/v8/n10/full/7401080.html

* focuses on Genomic Health's Oncotype DX test (based on expression levels) - predicts recurrence of breast cancer
* also mentions Roche's AmpliChip (based on CYP2D6 and CYP2C19 genes) - predicts drug metabolism
* and XDx AlloMap (based on expression levels) - predicts heart transplant rejection
* and Applied Genomics MammoStrat test (based on antibodies) - predicts recurrence of a particular breast cancer
* 70% of clinical decisions made by physicians in US are based on diagnostics (not necessarily GDx), but only 2% of $2 trillion annually spent on healthcare goes into diagnostics
** Clinically validating a test is probably "the biggest barrier to progress" says Doug Ross, Chief Scientific Officer of Applied Genomics.
** Genomic Health's Oncotype DX test was clinically validated with samples from the National Surgical Adjuvant Breast and Bowel Foundation (NSABP).
*** "Genomic Health's competitive advantage in the marketplace is derived in large part from the strength of the data from their published NSABP results," says Ross.
** so sharing of tissue samples for clinical trials to validate a GDx could be an important force encouraging collaboration.
=Navigation=
[[Category:Diagnostic_Kits]]
[http://cyber.law.harvard.edu/commonsbasedresearch/Diagnostic_Kits#Resources DK Bibliography]<br>
[[Diagnostic_Kits]]<br>
[[Main Page]]